Press releases

30 April, 2021

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announce that the number of shares and votes in the Company has increased by 32,601,360 as a result of a directed new issue of shares resolved by the Board of ...

29 April, 2021

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice o ...

27 April, 2021

Regulatory

Abliva AB publishes 2020 Annual report

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the English version of the Annual report for 2020 is now available on the company’s website, www.abliva.com.

19 April, 2021

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.

31 March, 2021

Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting (“EGM”) to be held on Thursday 29 April 2021.

30 March, 2021

Regulatory

Abliva has completed a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a biopharmaceutical company in the clinical phase that develops drugs for the treatment of rare and serious primary mitochondrial diseas ...

30 March, 2021

Regulatory

Abliva investigates the prerequisites for carrying out a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, toda ...

16 March, 2021

Abliva reports completion of KL1333 Phase 1a/b study

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced the completion ...

19 February, 2021

Regulatory

Abliva AB Year-End Report January – December 2020

2020 summary

20 January, 2021

Regulatory

Abliva

Press releases

Amended number of shares and votes in Abliva AB (publ)

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB publishes 2020 Annual report

Notice of Annual General Meeting of Abliva AB (publ)

Notice of Extraordinary General Meeting of Abliva AB (publ)

Abliva has completed a directed new issue

Abliva investigates the prerequisites for carrying out a directed new issue

Abliva reports completion of KL1333 Phase 1a/b study

Abliva AB Year-End Report January – December 2020

Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Ablivas KL1333 heading for phase II/III in 2021